Disclosures for "Efficacy and Safety of Extended-interval Dosing of Natalizumab in Multiple Sclerosis: A Systematic Review and Meta-analysis With Subgroup Evaluation"
-
Mr. Hammadeh has nothing to disclose.
-
Sadeen Eid has nothing to disclose.
-
Mr. Alnajjar has nothing to disclose.
-
Dr. Abu-Issa has nothing to disclose.
-
Dr. Alhallaq has nothing to disclose.
-
Mr. Almajmaie has nothing to disclose.
-
Dr. Badr has nothing to disclose.
-
Dr. Shawawrah has nothing to disclose.